Literature DB >> 14421725

Macroglobulinaemia. A clinical and pathological study.

N H MARTIN.   

Abstract

Entities:  

Keywords:  SERUM GLOBULIN

Mesh:

Substances:

Year:  1960        PMID: 14421725

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


× No keyword cloud information.
  10 in total

1.  PRIMARY MACROGLOBULINEMIA: DEATH DUE TO MESENTERIC VASCULAR OCCLUSION WITH GAS IN THE PORTAL VENOUS SYSTEM.

Authors:  A M EDWARDS; L B COSTOPOULOUS; H E BELL
Journal:  Can Med Assoc J       Date:  1964-12-19       Impact factor: 8.262

2.  FOUR CASES OF WALDENSTROEM'S MACROGLOBULINAEMIA.

Authors:  D A KOK; D N WHITMORE; R W AINSWORTH
Journal:  J Clin Pathol       Date:  1963-07       Impact factor: 3.411

3.  CHROMOSOMES AND SERUM PROTEINS: A LINKED ABNORMALITY.

Authors:  M W ELVES; M C ISRAUELS
Journal:  Br Med J       Date:  1963-10-26

4.  Treatment of macroglobulinaemia.

Authors:  N CONWAY; J M WALKER
Journal:  Br Med J       Date:  1962-11-17

5.  Macroglobulins. I. Studies on the isolation and physical properties of pathological macroglobulins.

Authors:  A ALBERT; P JOHNSON
Journal:  Biochem J       Date:  1961-12       Impact factor: 3.857

6.  Joint symptoms in myelomatosis and similar conditions.

Authors:  E B HAMILTON; E G BYWATERS
Journal:  Ann Rheum Dis       Date:  1961-12       Impact factor: 19.103

7.  Cytogenetic studies in a family with Waldenström's macroglobulinaemia.

Authors:  M W Elves; A K Brown
Journal:  J Med Genet       Date:  1968-06       Impact factor: 6.318

8.  Retinal abnormalities in diseases of the blood.

Authors:  J M Holt; E C Gordon-Smith
Journal:  Br J Ophthalmol       Date:  1969-03       Impact factor: 4.638

9.  Waldenström's macroglobulinemia: review of 45 cases.

Authors:  M Krajny; W Pruzanski
Journal:  Can Med Assoc J       Date:  1976-05-22       Impact factor: 8.262

10.  Waldenström's macroglobulinaemia treated with cylophosphamide and chlorambucil.

Authors:  R M Buckle; G C Jenkins; G L Mills
Journal:  J Clin Pathol       Date:  1966-01       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.